Adrenoceptor beta 2. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Propranolol CHEMBL27 |
Beta-2 adrenergic receptor antagonist Antagonist Small molecule |
✓ Both | 23 |
| Norepinephrine CHEMBL1437 |
Adrenergic receptor agonist Agonist Small molecule |
✓ Both | 21 |
| Carvedilol CHEMBL723 |
Adrenergic receptor beta antagonist Antagonist Small molecule |
✓ Both | 17 |
| Epinephrine CHEMBL679 |
Adrenergic receptor agonist Agonist Small molecule |
✓ Both | 10 |
| Dobutamine CHEMBL926 |
Beta-2 adrenergic receptor agonist Agonist Small molecule |
✓ Both | 6 |
| Esmolol CHEMBL768 |
Beta-2 adrenergic receptor antagonist Antagonist Small molecule |
✓ Both | 6 |
| Ephedrine CHEMBL211456 |
Adrenergic receptor agonist Agonist Small molecule |
ChEMBL only | 5 |
| Salbutamol CHEMBL714 |
Beta-2 adrenergic receptor agonist Agonist Small molecule |
✓ Both | 4 |
| Nebivolol CHEMBL434394 |
Beta-2 adrenergic receptor antagonist Antagonist Small molecule |
✓ Both | 4 |
| Labetalol CHEMBL429 |
Adrenergic receptor antagonist Antagonist Small molecule |
✓ Both | 3 |
| Isoproterenol CHEMBL434 |
Adrenergic receptor beta agonist Agonist Small molecule |
✓ Both | 2 |
| Salmeterol CHEMBL1263 |
Beta-2 adrenergic receptor agonist Agonist Small molecule |
✓ Both | 2 |
| Formoterol CHEMBL1256786 |
Beta-2 adrenergic receptor agonist Agonist Small molecule |
✓ Both | — |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Tachycardia | 4 | Phase 3 |
| Hypotensive disorder | 4 | Phase 3 |
| Ischemic stroke | 4 | Phase 3 |
| Pain | 3 | Phase 3 |
| Shock | 3 | Phase 3 |
| Cardiotoxicity | 3 | Phase 3 |
| Septic shock | 3 | Phase 3 |
| Cognitive impairment | 3 | Phase 2/3 |
| Acute lung injury | 3 | Phase 2 |
| Atrial fibrillation | 2 | Phase 3 |
| Brain edema | 2 | Phase 3 |
| Chronic kidney disease | 2 | Phase 3 |
| Cirrhosis of liver | 2 | Phase 3 |
| Congestive heart failure | 2 | Phase 3 |
| Epistaxis | 2 | Phase 3 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.
